The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Tezepelumab in Adults with Uncontrolled Asthma
Open accessAbstract
BACKGROUND: In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled despite treatment with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids. METHODS: In this phase 2, randomized, double-blind, placebo-controlled trial, we compared subcutaneous tezepelumab at three dose levels with placebo over a 52-week treatment period. The primary end point was the annualized rate of asthma exacerbations (events per patient-year) at week 52. RESULTS: The use of tezepelumab at a dose of 70 mg every 4 weeks (low dose; 145 patients), 210 mg every 4 weeks (medium dose; 145 patients), or 280 mg every 2 weeks (high dose; 146 patients) resulted in annualized asthma exacerbation rates at week 52 of 0.26, 0.19, and 0.22, respectively, as compared with 0.67 in the placebo group (148 patients). Thus, exacerbation rates in the respective tezepelumab groups were lower by 61%, 71%, and 66% than the rate in the placebo group (P<0.001 for all comparisons). Similar results were observed in patients regardless of blood eosinophil counts at enrollment. The prebronchodilator forced expiratory volume in 1 second at week 52 was higher in all tezepelumab groups than in the placebo group (difference, 0.12 liters with the low dose [P=0.01], 0.11 liters with the medium dose [P=0.02], and 0.15 liters with the high dose [P=0.002]). A total of 2 patients in the medium-dose group, 3 in the high-dose group, and 1 in the placebo group discontinued the trial regimen because of adverse events. CONCLUSIONS: Among patients treated with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids, those who received tezepelumab had lower rates of clinically significant asthma exacerbations than those who received placebo, independent of baseline blood eosinophil counts. (Funded by MedImmune [a member of the AstraZeneca Group] and Amgen; PATHWAY ClinicalTrials.gov number, NCT02054130 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200406-710st · Cited by 3,203
Dweik, R. A., Boggs, P. B., Erzurum, S. C., Irvin, C. G., Leigh, M. W., Lundberg, J. O., Olin, A.-C., Plummer, A. L., & Taylor, D. R. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.9120-11st · Cited by 2,539
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., Ortega, H. G., & Pavord, I. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403291 · Cited by 1,661
Type 2 inflammation in asthma — present in most, absent in many
Fahy, J. V. (2015) · Nature Reviews Immunology · doi:10.1038/nri3786 · Cited by 1,654
Global asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Self-citationBleecker, E. R., FitzGerald, J. M., Chanez, P., Papi, A., Weinstein, S. F., Barker, P., Sproule, S., Gilmartin, G., Aurivillius, M., Werkström, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31324-1 · Cited by 1,406
FitzGerald, J. M., Bleecker, E. R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., Ferguson, G. T., Busse, W. W., Barker, P., Sproule, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31322-8 · Cited by 1,397
Castro, M., Zangrilli, J., Wechsler, M. E., Bateman, E. D., Brusselle, G. G., Bardin, P., Murphy, K., Maspero, J. F., O'Brien, C., & Korn, S. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00042-9 · Cited by 1,182
Ying, S., O’Connor, B., Ratoff, J., Meng, Q., Mallett, K., Cousins, D., Robinson, D., Zhang, G., Zhao, J., Lee, T. H., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.8183 · Cited by 873
γ-Secretase-mediated proteolysis in cell-surface-receptor signalling
Fortini, M. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm910 · Cited by 824
Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
Gauvreau, G. M., O'Byrne, P. M., Boulet, L.-P., Wang, Y., Cockcroft, D., Bigler, J., FitzGerald, J. M., Boedigheimer, M., Davis, B. E., Dias, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402895 · Cited by 789
Self-citationAllakhverdi, Z., Comeau, M. R., Jessup, H. K., Yoon, B.-R. P., Brewer, A., Chartier, S., Paquette, N., Ziegler, S. F., Sarfati, M., & Delespesse, G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062211 · Cited by 786
TSLP Elicits IL-33–Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation
Kim, B. S., Siracusa, M. C., Saenz, S. A., Noti, M., Monticelli, L. A., Sonnenberg, G. F., Hepworth, M. R., Van Voorhees, A. S., Comeau, M. R., & Artis, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005374 · Cited by 731
Validation of a Standardized Version of the Asthma Quality of Life Questionnaire
Juniper, E. F., Buist, A. S., Cox, F. M., Ferrie, P. J., & King, D. R. (1999) · Chest · doi:10.1378/chest.115.5.1265 · Cited by 714
Sensing the outside world: TSLP regulates barrier immunity
Ziegler, S. F., & Artis, D. (2010) · Nature Immunology · doi:10.1038/ni.1852 · Cited by 560
Hanania, N. A., Alpan, O., Hamilos, D. L., Condemi, J. J., Reyes-Rivera, I., Zhu, J., Rosen, K. E., Eisner, M. D., Wong, D. A., & Busse, W. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00002 · Cited by 554
Ying, S., O’Connor, B., Ratoff, J., Meng, Q., Fang, C., Cousins, D., Zhang, G., Gu, S., Gao, Z., Shamji, B., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2790 · Cited by 402
Brightling, C. E., Chanez, P., Leigh, R., O'Byrne, P. M., Korn, S., She, D., May, R. D., Streicher, K., Ranade, K., & Piper, E. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00197-6 · Cited by 369
Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma
Shikotra, A., Choy, D. F., Ohri, C. M., Doran, E., Butler, C., Hargadon, B., Shelley, M., Abbas, A. R., Austin, C. D., Jackman, J., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.08.031 · Cited by 333
The Biology of Thymic Stromal Lymphopoietin (TSLP)
Ziegler, S. F., Roan, F., Bell, B. D., Stoklasek, T. A., Kitajima, M., & Han, H. (2013) · Advances in Pharmacology · doi:10.1016/b978-0-12-404717-4.00004-4 · Cited by 298
Zeiger, R. S., Schatz, M., Li, Q., Chen, W., Khatry, D. B., Gossage, D., & Tran, T. N. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2014.06.005 · Cited by 243
TSLP enhances the function of helper type 2 cells
Kitajima, M., Lee, H., Nakayama, T., & Ziegler, S. F. (2011) · European Journal of Immunology · doi:10.1002/eji.201041195 · Cited by 235
Asthma outcomes: Composite scores of asthma control
Cloutier, M. M., Schatz, M., Castro, M., Clark, N., Kelly, H. W., Mangione-Smith, R., Sheller, J., Sorkness, C., Stoloff, S., & Gergen, P. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.12.980 · Cited by 211
Lee, H.-C., Headley, M. B., Loo, Y.-M., Berlin, A., Gale, M., Debley, J. S., Lukacs, N. W., & Ziegler, S. F. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.031 · Cited by 194
Asthma outcomes: Pulmonary physiology
Tepper, R. S., Wise, R. S., Covar, R., Irvin, C. G., Kercsmar, C. M., Kraft, M., Liu, M. C., O'Connor, G. T., Peters, S. P., Sorkness, R., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.12.986 · Cited by 177
Asthma outcomes: Quality of life
Wilson, S. R., Rand, C. S., Cabana, M. D., Foggs, M. B., Halterman, J. S., Olson, L., Vollmer, W. M., Wright, R. J., & Taggart, V. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.12.988 · Cited by 166
Nakamura, Y., Miyata, M., Ohba, T., Ando, T., Hatsushika, K., Suenaga, F., Shimokawa, N., Ohnuma, Y., Katoh, R., Ogawa, H., et al. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.09.022 · Cited by 158
Bateman, E. D., Bousquet, J. J., Busse, W. W., Clark, T. J. H., Gul, N., Gibbs, M., & Pedersen, S. S. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01724.x · Cited by 110
Bleck, B., Tse, D. B., de Lafaille, M. A. C., Zhang, F., & Reibman, J. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9149-0 · Cited by 107
TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling
Zhong, J., Sharma, J. N., Raju, R., Palapetta, S. M., Prasad, T. S. K., Huang, T., Yoda, A., Tyner, J. W., van Bodegom, D., Weinstock, D. M., et al. (2014) · Database · doi:10.1093/database/bau007 · Cited by 104
Calvén, J., Yudina, Y., Hällgren, O., Westergren‐Thorsson, G., Davies, D. E., Brandelius, A., & Uller, L. (2011) · Journal of Innate Immunity · doi:10.1159/000329131 · Cited by 88
A TSLP-complement axis mediates neutrophil killing of methicillin-resistant Staphylococcus aureus
West, E. E., Spolski, R. J., Kazemian, M., Yu, Z., Kemper, C., & Leonard, W. J. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8471 · Cited by 55
Research works printed but not linked: 1
- 10.1159/000106319 · doi:10.1159/000106319
Cited by
Papi, A., Brightling, C., Pedersen, S. E., & Reddel, H. K. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33311-1 · Cited by 1,759
The basic immunology of asthma
Hammad, H., & Lambrecht, B. N. (2021) · Cell · doi:10.1016/j.cell.2021.02.016 · Cited by 1,105
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
Menzies-Gow, A., Corren, J., Bourdin, A., Chupp, G., Israel, E., Wechsler, M. E., Brightling, C. E., Griffiths, J. M., Hellqvist, Å., Bowen, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034975 · Cited by 1,056
Self-citationLambrecht, B. N., Hammad, H., & Fahy, J. V. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.018 · Cited by 1,039
TH2 cell development and function
Walker, J. A., & McKenzie, A. N. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.118 · Cited by 632
Metadata
- Authors
- Corren, J., Parnes, J. R., Wang, L., Mo, M., Roseti, S. L., Griffiths, J. M., & van der Merwe, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-09-07
- Volume
- 377
- Issue
- 10
- Pages
- 936-946
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752584372
- Cited by
- 965
- References
- 38
- FWCI
- 60.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.